Castañeda Kelly Melisa, de Waard Jolien, Slagter-Menkema Lorian, Mastik Mirjam, Vuijk Floris Adriaan, Bekkers Rudolf Lambertus Maria, de Bock Geertruida Hendrika, Wisman Gijsbertha Barendina Alida, Schuuring Ed
Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
J Med Virol. 2025 Jul;97(7):e70461. doi: 10.1002/jmv.70461.
High-risk HPV (hrHPV) is the necessary cause of cervical cancer with HPV16/18 accounting for around 70% of the cases worldwide, while other non-HPV16/18 hrHPV genotypes prevail in ~95% of high-grade lesions. Understanding regional genotype distribution of hrHPV types not covered by the nonavalent vaccine is crucial for evaluating vaccine effectiveness and enhancing population-based screening (PBS). The objective of the present study is to update hrHPV genotype prevalence in a non-vaccinated cohort of 1200 hrHPV-positive women from the Dutch PBS using INNO-LiPA HPV Genotyping Extra-II to identify 32 individual HPV genotypes in self-sampled material. HrHPV prevalence for all 32 genotypes, also grouped by bivalent, quadrivalent, and nonavalent vaccine types (2vHPV, 4vHPV, and 9vHPV), was reported by histologic diagnosis and age. The most common genotypes were HPV16 (394,33%), especially in younger women, followed by HPV31 (216,18%) and HPV52 (199,17%). 2vHPV genotypes were found in 23% (n = 90) of NILM cases, 27% (n = 84) of CIN0/CIN1, 45% (n = 74) of CIN2, 71% (n = 219) of CIN3, and 92% (n = 12) of cervical cancers. In comparison, 9vHPV genotypes appeared in 60% (n = 240) of NILM, 69% (n = 218) of CIN0/CIN1, 88% (n = 145) of CIN2, 94% (n = 289) of CIN3, and all cervical cancers (n = 13). HrHPV types not included in 9vHPV had an overall prevalence of 19% (n = 225), with 88% (197/225) found in NILM or CIN0/CIN1. This study highlights vaccine-type HPV in all cancer cases and many high-grade lesions, reinforcing the need for improved vaccination efforts and broader protection.
高危型人乳头瘤病毒（hrHPV）是宫颈癌的必要病因，其中HPV16/18在全球约70%的病例中出现，而其他非HPV16/18的hrHPV基因型在约95%的高级别病变中占主导。了解九价疫苗未覆盖的hrHPV类型的区域基因型分布对于评估疫苗有效性和加强基于人群的筛查（PBS）至关重要。本研究的目的是使用INNO-LiPA HPV基因分型Extra-II更新来自荷兰PBS的1200名hrHPV阳性未接种疫苗女性队列中的hrHPV基因型流行情况，以识别自取样材料中的32种个体HPV基因型。按组织学诊断和年龄报告了所有32种基因型的hrHPV流行情况，也按二价、四价和九价疫苗类型（2vHPV、4vHPV和9vHPV）进行了分组。最常见的基因型是HPV16（394例，33%），尤其是在年轻女性中，其次是HPV31（216例，18%）和HPV52（199例，17%）。2vHPV基因型在23%（n = 90）的阴性非典型鳞状细胞病例、27%（n = 84）的CIN0/CIN1、45%（n = 74）的CIN2、71%（n = 219）的CIN3和92%（n = 12）的宫颈癌中被发现。相比之下，9vHPV基因型出现在60%（n = 240）的阴性非典型鳞状细胞、69%（n = 218）的CIN0/CIN1、88%（n = 145）的CIN2、94%（n = 289）的CIN3以及所有宫颈癌（n = 13）中。九价疫苗未包含的hrHPV类型总体流行率为19%（n = 225），其中88%（197/225）出现在阴性非典型鳞状细胞或CIN0/CIN1中。本研究强调了在所有癌症病例和许多高级别病变中疫苗型HPV的情况，强化了加强疫苗接种工作和扩大保护范围的必要性。
